Patents Assigned to Watchmaker Genomics, Inc.
  • Publication number: 20260193705
    Abstract: This disclosure provides methods of fragmenting RNA:DNA hybrids. These methods can be used to improve preparation of RNA for next-generation sequencing.
    Type: Application
    Filed: March 9, 2026
    Publication date: July 9, 2026
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Ross Wadsworth, Lee French, Bryce Foster, Lianna Kapp
  • Patent number: 12630862
    Abstract: The invention provides sets of RNA depletion probes, short DNA oligos that hybridize along the length of a target RNA and mediate digestion of the target RNA by RNase H to remove super-abundant RNA molecules from a sample. Depletion probes according to the invention are designed foremost based on biochemistry and the biophysical properties of the probes so that all of the depletion probes of a set exhibit substantially uniform, consistent behavior in binding to a target RNA in a sample. Probes are principally designed to specific performance targets and biophysical properties, yielding probe sets with irregular, even apparently random, spacing along a target RNA molecule.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: May 19, 2026
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Travis J. Sanders, Martin Ranik, Brian A. Kudlow
  • Patent number: 12601004
    Abstract: The invention provides sets of RNA depletion probes, short DNA oligos that hybridize along the length of a target RNA and mediate digestion of the target RNA by RNase H to remove super-abundant RNA molecules from a sample. Depletion probes according to the invention are designed foremost based on biochemistry and the biophysical properties of the probes so that all of the depletion probes of a set exhibit substantially uniform, consistent behavior in binding to a target RNA in a sample. Probes are principally designed to specific performance targets and biophysical properties, yielding probe sets with irregular, even apparently random, spacing along a target RNA molecule.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: April 14, 2026
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Travis J. Sanders, Martin Ranik, Brian A. Kudlow
  • Patent number: 12571041
    Abstract: This disclosure provides methods of fragmenting RNA:DNA hybrids. These methods can be used to improve preparation of RNA for next-generation sequencing.
    Type: Grant
    Filed: October 31, 2025
    Date of Patent: March 10, 2026
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Ross Wadsworth, Lee French, Bryce Foster, Lianna Kapp
  • Publication number: 20260042864
    Abstract: This disclosure relates to Taq polymerase binding antibody compositions and methods of use for nucleic acid amplification.
    Type: Application
    Filed: August 7, 2025
    Publication date: February 12, 2026
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Phillip Venter, Bjame Faurholm, Eric van der Walt
  • Publication number: 20250388879
    Abstract: The present invention provides MML V reverse transcriptase enzymes with increased thermal stability as compared with wild type MML V and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.
    Type: Application
    Filed: August 26, 2025
    Publication date: December 25, 2025
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Julie Walker, Bjarne Faurholm, Ross Wadsworth, Brian A. Kudlow
  • Patent number: 12503690
    Abstract: The present invention provides MML V reverse transcriptase enzymes with increased thermal stability as compared with wild type MML V and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.
    Type: Grant
    Filed: August 26, 2025
    Date of Patent: December 23, 2025
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Julie Walker, Bjarne Faurholm, Ross Wadsworth, Brian A. Kudlow
  • Publication number: 20250340865
    Abstract: Disclosed herein, in part, are methods and compositions for performing high throughput screens of enzyme activity.
    Type: Application
    Filed: April 2, 2025
    Publication date: November 6, 2025
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Leonidas Karamanof, Eric van der Walt, Bjarne Faurholm, Michiel Theodoor van Diepen, David Lloyd Matten, Campbell McDuling, Daniel Henri Le Jeune, Thomas Harrison, Brian Kudlow
  • Patent number: 12410469
    Abstract: Disclosed herein are methods and compositions for normalizing polynucleotide concentration. Normalizing may be accomplished using polynucleotide binding proteins (e.g., catalytically inactive CRISPR protein or catalytically inactive Argonaute proteins). The polynucleotide binding proteins may bind to the adapter sequences of a target polynucleotide. Thus, adding the same amount of a polynucleotide binding proteins to different samples and then extracting the polynucleotide protein is shown herein to extract similar amounts of target polynucleotides from the different samples.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: September 9, 2025
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Martin Ranik, Eric van der Walt, Clara Ross, Craig Marshall, Lindsay Peterkin, Brian Kudlow, Travis J. Sanders
  • Publication number: 20250197821
    Abstract: The present invention provides MMLV reverse transcriptase enzymes with increased thermal stability as compared with wild type MMLV and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.
    Type: Application
    Filed: March 7, 2023
    Publication date: June 19, 2025
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Julie Walker, Bjarne Faurholm, Ross Wadsworth, Brian A. Kudlow
  • Publication number: 20240229115
    Abstract: Disclosed herein are methods and compositions for normalizing polynucleotide concentration. Normalizing may be accomplished using polynucleotide binding proteins (e.g., catalytically inactive CRISPR protein or catalytically inactive Argonaute proteins). The polynucleotide binding proteins may bind to the adapter sequences of a target polynucleotide. Thus, adding the same amount of a polynucleotide binding proteins to different samples and then extracting the polynucleotide protein is shown herein to extract similar amounts of target polynucleotides from the different samples.
    Type: Application
    Filed: October 23, 2023
    Publication date: July 11, 2024
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Martin Ranik, Eric van der Walt, Clara Ross, Craig Marshall, Lindsay Peterkin, Brian Kudlow
  • Publication number: 20240132942
    Abstract: Disclosed herein are methods and compositions for normalizing polynucleotide concentration. Normalizing may be accomplished using polynucleotide binding proteins (e.g., catalytically inactive CRISPR protein or catalytically inactive Argonaute proteins). The polynucleotide binding proteins may bind to the adapter sequences of a target polynucleotide. Thus, adding the same amount of a polynucleotide binding proteins to different samples and then extracting the polynucleotide protein is shown herein to extract similar amounts of target polynucleotides from the different samples.
    Type: Application
    Filed: October 22, 2023
    Publication date: April 25, 2024
    Applicant: Watchmaker Genomics, Inc.
    Inventors: Martin Ranik, Eric van der Walt, Clara Ross, Craig Marshall, Lindsay Peterkin, Brian Kudlow
  • Patent number: 11639499
    Abstract: The present invention provides MMLV reverse transcriptase enzymes with increased thermal stability as compared with wild type MMLV and AMV reverse transcriptases. The improved thermal stability allows for reverse transcription of RNA to cDNA at temperatures above 37° C., thereby reducing error rates introduced during cDNA synthesis. As a result, the reverse transcriptases of the invention allow for increased accuracy in the determination of transcriptomes of living organisms.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: May 2, 2023
    Assignee: Watchmaker Genomics, Inc.
    Inventors: Julie Walker, Bjarne Faurholm, Ross Wadsworth, Brian A. Kudlow